Table 2.
Selected cost parameters used in a computer simulation of antiretroviral therapy strategies following exposure to single-dose nevirapine.
| Costs (2008 US dollars) | ||
|---|---|---|
| Antiretroviral therapy (monthly cost) a | Clinton Foundation12 | |
| NVP/TDF/FTC | $15.44 | Clinton Foundation12 |
| LPV/r/TDF/FTC | $50.39 | Clinton Foundation12 |
| NVP/ddI/ZDV | $23.73 | Clinton Foundation12 |
| LPV/r/ddI/ZDV | $58.68 | Clinton Foundation12 |
| “3rd-line/maintance” LPV/r/3TC | $40.96 | Clinton Foundation12 |
| 3rd line DRV/r/3TC (sensitivity analysis) | $100.93 | Médecins Sans Frontieres50 Cape Town AIDS Cohort,14 |
| Clinical care | Health Systems Trust15 | |
| Care for acute opportunistic infection (per event) | $10.71-$3330.71 | |
| Minor/moderate drug toxicity (per event) | $10.71 | |
| Major/severe drug toxicity (per event) | $1545.99 | |
| Chronic care (monthly cost) | ||
| CD4<200/μL | $51.69–129.25 | |
| CD4>200/μL | $9.84–20.77 | |
| Terminal care (last month of life) | $536.09 | |
| Laboratory monitoring (per assay) | Health Systems Trust15 | |
| CD4 test | $9.42 | |
| Viral load test (sensitivity analysis) | $47.08 | |
NVP: nevirapine; LPV/r: lopinavir/ritonavir; TDF: tenofovir; FTC: emtricitabine; ZDV: zidovudine; ddI: didanosine; DRV/r: darunavir; 3TC: lamivudine
a
Individual monthly drug costs: nevirapine $3.25, lopinavir/ritonavir $38.20